These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

350 related items for PubMed ID: 21595177

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. [The meaning of biologic therapy in the treatment of rheumatoid arthritis with the focus on clinical remission. Part I. Tumor necrosis factor alpha inhibitors].
    Swierkot J, Madej M.
    Pol Merkur Lekarski; 2011 Apr; 30(178):283-8. PubMed ID: 21595176
    [Abstract] [Full Text] [Related]

  • 4. Survival on treatment with second-line biologic therapy: a cohort study comparing cycling and swap strategies.
    Favalli EG, Biggioggero M, Marchesoni A, Meroni PL.
    Rheumatology (Oxford); 2014 Sep; 53(9):1664-8. PubMed ID: 24729445
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. The 'Switch' study protocol: a randomised-controlled trial of switching to an alternative tumour-necrosis factor (TNF)-inhibitor drug or abatacept or rituximab in patients with rheumatoid arthritis who have failed an initial TNF-inhibitor drug.
    Navarro Coy NC, Brown S, Bosworth A, Davies CT, Emery P, Everett CC, Fernandez C, Gray JC, Hartley S, Hulme C, Keenan AM, McCabe C, Redmond A, Reynolds C, Scott D, Sharples LD, Pavitt S, Buch MH.
    BMC Musculoskelet Disord; 2014 Dec 23; 15():452. PubMed ID: 25539805
    [Abstract] [Full Text] [Related]

  • 7. Biologic therapy for rheumatoid arthritis: clinical efficacy and predictors of response.
    Gibbons LJ, Hyrich KL.
    BioDrugs; 2009 Dec 23; 23(2):111-24. PubMed ID: 19489652
    [Abstract] [Full Text] [Related]

  • 8. Rheumatoid arthritis: Biological therapy other than anti-TNF.
    Rossi D, Modena V, Sciascia S, Roccatello D.
    Int Immunopharmacol; 2015 Aug 23; 27(2):185-8. PubMed ID: 25840282
    [Abstract] [Full Text] [Related]

  • 9. Perspectives on rheumatoid arthritis for the orthopedic surgeon: overview of non-tumor necrosis factor biologic drugs and perioperative management.
    Keith MP.
    Am J Orthop (Belle Mead NJ); 2011 Dec 23; 40(12):E272-5. PubMed ID: 22268021
    [Abstract] [Full Text] [Related]

  • 10. Strategies after the failure of the first anti-tumor necrosis factor alpha agent in rheumatoid arthritis.
    Papagoras C, Voulgari PV, Drosos AA.
    Autoimmun Rev; 2010 Jun 23; 9(8):574-82. PubMed ID: 20433955
    [Abstract] [Full Text] [Related]

  • 11. Therapeutic agents for patients with rheumatoid arthritis and an inadequate response to tumour necrosis factor-alpha antagonists.
    Isaacs JD.
    Expert Opin Biol Ther; 2009 Dec 23; 9(12):1463-75. PubMed ID: 19916731
    [Abstract] [Full Text] [Related]

  • 12. Malignant Neoplasms in Patients With Rheumatoid Arthritis Treated With Tumor Necrosis Factor Inhibitors, Tocilizumab, Abatacept, or Rituximab in Clinical Practice: A Nationwide Cohort Study From Sweden.
    Wadström H, Frisell T, Askling J, Anti-Rheumatic Therapy in Sweden (ARTIS) Study Group.
    JAMA Intern Med; 2017 Nov 01; 177(11):1605-1612. PubMed ID: 28975211
    [Abstract] [Full Text] [Related]

  • 13. New therapies for treatment of rheumatoid arthritis.
    Smolen JS, Aletaha D, Koeller M, Weisman MH, Emery P.
    Lancet; 2007 Dec 01; 370(9602):1861-74. PubMed ID: 17570481
    [Abstract] [Full Text] [Related]

  • 14. Biological therapy for rheumatoid arthritis: where are we now?
    Horton SC, Emery P.
    Br J Hosp Med (Lond); 2012 Jan 01; 73(1):12-8. PubMed ID: 22241404
    [Abstract] [Full Text] [Related]

  • 15. [Non-TNF biologicals in the therapeutic strategy for rheumatoid arthritis].
    Wollenhaupt J, Krüger K.
    Z Rheumatol; 2010 Sep 01; 69(7):618-25. PubMed ID: 20703488
    [Abstract] [Full Text] [Related]

  • 16. Comparative effectiveness of rituximab, abatacept, and tocilizumab in adults with rheumatoid arthritis and inadequate response to TNF inhibitors: prospective cohort study.
    Gottenberg JE, Morel J, Perrodeau E, Bardin T, Combe B, Dougados M, Flipo RM, Saraux A, Schaeverbeke T, Sibilia J, Soubrier M, Vittecoq O, Baron G, Constantin A, Ravaud P, Mariette X, French Society of Rheumatology and the investigators participating in AIR, ORA, and REGATE registries.
    BMJ; 2019 Jan 24; 364():l67. PubMed ID: 30679233
    [Abstract] [Full Text] [Related]

  • 17. Sequential use of biologic therapy in rheumatoid arthritis.
    Buch MH.
    Curr Opin Rheumatol; 2010 May 24; 22(3):321-9. PubMed ID: 20190641
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. The issue of comparators in economic evaluations of biologic response modifiers in rheumatoid arthritis.
    Tsao NW, Bansback NJ, Shojania K, Marra CA.
    Best Pract Res Clin Rheumatol; 2012 Oct 24; 26(5):659-76. PubMed ID: 23218430
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 18.